Pozen shares sink on new demand for data

Shares of Pozen sank about 10 percent this morning after it announced that the FDA had asked for more data on the migraine drug Trexima--a combination of sumatriptan and naproxen sodium--before it can be approved. The Trexima application had already been found wanting last June. This new warning came after the agency found the company's response insufficient. Pozen says it will submit more information by the end of the year, but adds that it feels the data already demonstrates the drug's superiority to sumatriptan.

- check out the company's press release
- here's the report on Pozen from TheStreet.com

Related Articles:
Pozen shares soar on rich pain med deal. Report
Pozen loses latest bid for FDA approval of MT100. Report
Pozen files NDA for new migraine treatment. Report